-- Lexington, MA-based Gene Therapy
Facility Recognized for Enabling Manufacturing Excellence --
LEXINGTON, Mass. and AMSTERDAM, the
Netherlands, March 03, 2017 (GLOBE NEWSWIRE) -- uniQure N.V.
(NASDAQ:QURE), a leader in human gene therapy, today announced that
it has been recognized by Frost & Sullivan as a 2017
Manufacturing Leadership Awards winner for outstanding achievement
in Engineering & Production Technology Leadership related to
its Lexington, Massachusetts gene therapy manufacturing
facility.
uniQure's Lexington-based facility is
one of the largest, most versatile gene therapy manufacturing
facilities in the world. Over the past four years, uniQure
has invested more than $25 million in designing, constructing and
equipping its 55,000 square foot facility with state-of-the-art
laboratories and commercial-scale production capabilities. The
facility offers 500-liter capacity with the ability to expand to up
to 2,000 liters when needed.
"The innovative design of our
facility, which incorporated 3D modeling and single-use components,
required substantially less upfront capital expenditures and
enables us to operate at significantly lower costs compared to
other production systems," stated Lance Weed, vice president of
operations for uniQure. "Our use of disposable components in our
manufacturing process reduces the need for maintenance and testing,
lowers the risk of contamination, enables rapid product
changeovers, and requires substantially less personnel to
operate."
"uniQure is committed to
manufacturing excellence in gene therapy and we are delighted that
Frost & Sullivan has recognized our achievements in this
regard," stated Matt Kapusta, chief executive officer of
uniQure. "We continue to believe that our leading
manufacturing capabilities provide us a significant competitive
advantage in rapidly delivering gene therapies to patients,
including our lead product candidate in hemophilia B, for which we
plan to begin a global pivotal study in 2018."
uniQure will be recognized at the
13th Annual Manufacturing Leadership Awards Gala, which is to be
held on the last day of the Manufacturing Leadership Summit, June
12-14, 2017 at the Hyatt Regency Huntington Beach Resort and Spa in
Huntington Beach, CA.
Additional Resources
- 2017 Manufacturing Leadership
Award Winners
- About the 13th Annual
Manufacturing Leadership Summit
- About the Manufacturing and
Leadership Council
- About Frost and
Sullivan
About uniQure
uniQure is delivering on the promise of gene therapy - single
treatments with potentially curative results. We are leveraging our
modular and validated technology platform to rapidly advance a
pipeline of proprietary and partnered gene therapies to treat
patients with hemophilia, Huntington's disease and cardiovascular
diseases. www.uniQure.com
About the Frost & Sullivan Manufacturing Leadership
Awards
The Frost & Sullivan Manufacturing Leadership Awards, now in
their 13th year, honor manufacturing companies and individual
manufacturing leaders that are shaping the future of global
manufacturing. Winning projects and individual manufacturing
leaders have demonstrated achievement in one of a wide range of
categories, and are chosen by a panel of expert
judges for results that have delivered clear and compelling
value, return on investment, and other tangible outcomes. There
will be several winners in each category, including one High
Achiever's Award in each category, as well as a 2017 Manufacturer
of the Year for both small and large enterprises. Also unveiled at
the Gala will be the ML Awards Manufacturing Leader of the Year and
Lifetime Achievement Award winners.
The theme for the 13th Annual
Manufacturing Leadership Summit is "Manufacturing 4.0 in Action."
The event enables senior-level executives in all aspects of
manufacturing an opportunity to network with and learn from the
best minds in the industry
For more information on the
Manufacturing Leadership Awards or the Manufacturing Leadership
Summit, please go to www.mlsummit.com.
uniQure Forward-Looking Statements
This press release contains
forward-looking statements. All statements other than statements of
historical fact are forward-looking statements, which are often
indicated by terms such as "anticipate," "believe," "could,"
"estimate," "expect," "goal," "intend," "look forward to", "may,"
"plan," "potential," "predict," "project," "should," "will,"
"would" and similar expressions. Forward-looking statements are
based on management's beliefs and assumptions and on information
available to management only as of the date of this press release.
These forward-looking statements include, but are not limited to,
statements regarding the implementation and effects of the
Company's new strategic and organizational changes, the development
of our gene therapy product candidates, the success of our
collaborations and the risk of cessation, delay or lack of success
of any of our ongoing or planned clinical studies and/or
development of our product candidates. Our actual results could
differ materially from those anticipated in these forward-looking
statements for many reasons, including, without limitation, risks
associated with corporate reorganizations and strategic shifts,
collaboration arrangements, our and our collaborators' clinical
development activities, regulatory oversight, product
commercialization and intellectual property claims, as well as the
risks, uncertainties and other factors described under the heading
"Risk Factors" in uniQure's 2015 Annual Report on Form 20-F filed
with the Securities and Exchange Commission on April 4, 2016. Given
these risks, uncertainties and other factors, you should not place
undue reliance on these forward-looking statements, and we assume
no obligation to update these forward-looking statements, even if
new information becomes available in the future.